A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer-Reference-Cited by-同舟云学术

A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer

Published:2022-05-13 Issue:11 Volume:65 Page:2205-2217
ISSN:1674-7305
Container-title:Science China Life Sciences
language:en
Short-container-title:Sci. China Life Sci.

Author:

Gong Chang,Cheng Ziliang,Yang Yaping,Shen Jun,Zhu Yingying,Ling Li,Lin Wanyi,Yu Zhigang,Li Zhihua,Tan Weige,Zheng Chushan,Zheng Wenbo,Zhong Jiajie,Zhang Xiang,Zeng Yunjie,Liu Qiang,Huang R. Stephanie,Komorowski Andrzej L.,Yang Eddy S.,Bertucci François,Ricci Francesco,Orlandi Armando,Franceschini Gianluca,Takabe Kazuaki,Klimberg Suzanne,Ishii Naohiro,Toss Angela,Tan Mona P.,Cherian Mathew A.,Song Erwei

Publisher

Springer Science and Business Media LLC

Subject

General Agricultural and Biological Sciences,General Environmental Science,General Biochemistry, Genetics and Molecular Biology

Link

https://link.springer.com/content/pdf/10.1007/s11427-022-2104-3.pdf

Reference53 articles.

1. Asaoka, M., Gandhi, S., Ishikawa, T., and Takabe, K. (2020). Neoadjuvant chemotherapy for breast cancer: past, present, and future. Breast Cancer 14, 117822342098037.

2. Bear, H.D., Anderson, S., Brown, A., Smith, R., Mamounas, E.P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D.L., et al. (2003). The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21, 4165–4174.

3. Board, W.C.O.T.E. (2019). Breast Tumors. Lyon (France): International Agency for Research on Cancer. Available from URL: https://publications.iarc.fr/581.

4. Chen, B., Tang, H., Liu, X., Liu, P., Yang, L., Xie, X., Ye, F., Song, C., Xie, X., and Wei, W. (2015). MiR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. Cancer Lett 356, 410–417.

5. Chen, T., Zhang, N., Moran, M.S., Su, P., Haffty, B.G., and Yang, Q. (2018). Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysis. Clin Breast Cancer 18, 1–8.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive study on epigenetic signatures to monitor disease progression and the response to therapy in breast cancer;Biomedical Analysis;2024-09

2. Correlation and predictive value of pathological complete response and ultrasound characteristic parameters in neoadjuvant chemotherapy for breast;World Journal of Clinical Cases;2024-08-16

3. The p38/MAPK pathway as a therapeutic target to prevent therapeutic escape of breast cancer stem cells;Science China Life Sciences;2024-06-26

4. Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway;Science China Life Sciences;2024-06-17

5. Early-onset and later-onset cancer: trends, risk factors, and prevention in Northern China;Science China Life Sciences;2024-05-23